Tag: Fudan-University

4 articles

Policy & Regulation

Chinese Academy of Sciences names brain-computer interfaces a priority field in its 2026 to 2030 plan

The Chinese Academy of Sciences (CAS), China's top state research body, announced on 28 September 2026 that it had released its 15th Five-Year development plan covering 2026 to 2030. The plan lists brain-computer interfaces among its 'important priority fields' (重要优先领域), alongside integrated circuits, artificial intelligence, quantum science and technology, life sciences and biotechnology, and controlled nuclear fusion. CAS will organise research around a '3+4+X' regional layout with Shanghai as one of three strategic highlands, and will explore forming field-based research consortia, mission-based task forces and platform-based facility clusters across its institutes. CAS already runs its own invasive BCI programme: a system developed at its Shanghai Center for Excellence in Brain Science and Intelligence Technology (CEBSIT) was implanted in its first trial participant at Huashan Hospital in March 2025, and StairMed, founded by CEBSIT researcher Zhao Zhengtuo, entered the National Medical Products Administration's innovative device green channel in November 2025 with a market target of around 2028. CAS was one of the seven co-signatories of the 2025 BCI industry implementation opinions. The plan lands six days after Premier Li Qiang inspected BCI products in Shanghai and called future industries a blue ocean for advanced manufacturing. No BCI budget, programme names or milestones have been made public.

Sep 30

Industry News

Arbor Neuroscience CEO Philip Sabes tells Shanghai BCI symposium that prediction is the neuromodulation bottleneck

Philip Sabes, a Neuralink co-founder (full-time 2017 to 2020) and now CEO of Arbor Neuroscience, delivered a keynote at the BCI Inno+ Salon International Symposium on Brain-Computer Interface in Shanghai on 14 September 2026. His stated thesis was that the real bottleneck in neuromodulation is prediction: because clinicians cannot reliably predict what will happen after brain stimulation, treatment outcomes are inconsistent. Sabes summarised current practice as 'poke and hope' and positioned Arbor's approach as 'predict and treat'. Arbor Neuroscience is the September 2026 rebrand of Forest Neurotech, a functional-ultrasound-imaging Focused Research Organization founded by Sumner Norman, Tyson Aflalo and Will Biederman inside Convergent Research. The symposium was hosted by the BCI Innovation and Transformation Center at Brain Intelligence World in Shanghai's Minhang District, a Shanghai state-backed partnership between Minhang District, Lingang Group, Shanghai State Investment Corp and Huashan Hospital (a Fudan University teaching hospital), positioned as China's first BCI industry cluster. Sabes made no public statement on US and China BCI competition, export controls, or the recent NSCEB and BIS enforcement actions.

Sep 19

Industry News

StairMed's penetrating BCI trial at Huashan reaches 18 cumulative implants

On 20 July 2026, at the World Artificial Intelligence Conference in Shanghai, StairMed disclosed that its cortex-penetrating invasive BCI clinical trial at Huashan Hospital has now reached 18 cumulative implants since March 2025. The Shanghai firm co-founded by Zhao Zhengtuo and Xue Li at the Chinese Academy of Sciences' Center for Excellence in Brain Science demonstrated a patient three months post-op controlling a wheelchair by thought and hitting 6.19 bits per second on a cursor task, alongside a live journalist test at 4.9 bits per second with a finger.

Jul 20

Industry News

China performs first commercial Neuracle NEO implant

On Monday 13 July 2026, neurosurgeons at Huashan Hospital affiliated with Fudan University performed the first commercial implantation of Neuracle's NEO brain-computer interface in a male patient with tetraplegia from a decade-old cervical spinal cord injury. The device is coin-sized, epidural, battery-free, and drives a pneumatic glove for hand grasping. Neuracle NEO is the world's first commercial invasive brain-computer interface implant for motor restoration in paralysis, following NMPA Class III market approval on 13 March 2026.

Jul 16